NDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
9
Data completeness
5/8 — Partial
SIMBRINZA (brinzolamide/brimonidine tartrate) by Alcon is carbonic anhydrase inhibitors [moa]. First approved in 2013.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIMBRINZA is a fixed-dose combination ophthalmic suspension containing brinzolamide (carbonic anhydrase inhibitor) and brimonidine tartrate (alpha-2 adrenergic agonist) approved for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by decreasing aqueous humor production through dual mechanisms—enzyme inhibition and sympathomimetic activity. The product represents a convenient once-daily or twice-daily regimen for glaucoma management.
$76MPart D
Peak4.2 years to LOEProduct is at peak commercial maturity with ~278K annual Part D claims, indicating stable established franchise requiring defense-focused commercial strategies as LOE approaches.
Mechanism of Action
Carbonic Anhydrase Inhibitors
Pharmacologic Class:
Carbonic Anhydrase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
Started Jun 2016
173 enrolled
Open-angle GlaucomaOcular Hypertension
24-hr Intraocular Pressure Control With SIMBRINZA ®
Started May 2016
162 enrolled
Glaucoma
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
Started Aug 2015
290 enrolled
Open-Angle GlaucomaOcular Hypertension
A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
Started Nov 2014
150 enrolled
Open-Angle GlaucomaOcular Hypertension
The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure
Started Aug 2014
60 enrolled
Open Angle GlaucomaOcular HypertensionPigment Dispersion Syndrome+1 more
Worked on SIMBRINZA at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.